BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30560935)

  • 1. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
    Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
    Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
    Gene; 2021 May; 782():145533. PubMed ID: 33636291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
    Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
    J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles.
    Wang D; Liu X; Wei M; Qian C; Song S; Chen J; Wang Z; Xu Q; Yang Y; He M; Chi X; Huang S; Li T; Kong Z; Zheng Q; Yu H; Wang Y; Zhao Q; Zhang J; Xia N; Gu Y; Li S
    Nat Commun; 2020 Jun; 11(1):2841. PubMed ID: 32503989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
    Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.
    Gersch ED; Gissmann L; Garcea RL
    Antivir Ther; 2012; 17(3):425-34. PubMed ID: 22293302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
    Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
    Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
    Schellenbacher C; Kwak K; Fink D; Shafti-Keramat S; Huber B; Jindra C; Faust H; Dillner J; Roden RBS; Kirnbauer R
    J Invest Dermatol; 2013 Dec; 133(12):2706-2713. PubMed ID: 23752042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
    Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
    Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
    Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
    Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
    J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.
    Gupta SK; Singh A; Srivastava M; Gupta SK; Akhoon BA
    Vaccine; 2009 Dec; 28(1):120-31. PubMed ID: 19799841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.